FIELD: pharmacology.
SUBSTANCE: for CD89 activation neutrophil therapy, inflammations previously activated by a stimulus, are brought into contact with an effective dose of molecules that activate CD89 and contain Fc-alpha.
EFFECT: CD89 activation increases apoptosis in neutrophils, which provides inhibition of inflammation in autoimmune and inflammatory diseases.
18 cl, 13 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTI-SPECIFIC OR BISPECIFIC MOLECULE (VERSIONS), METHOD FOR ELIMINATION OR DECREASING QUANTITY OF TARGET CELLS IN SUBJECT'S BODY, METHOD FOR TREATING PATHOGEN-INFECTED SUBJECT AND METHOD FOR SUBJECT'S VACCINATION | 1997 |
|
RU2201766C2 |
| IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USING | 2006 |
|
RU2444528C2 |
| MONOCLONAL ANTI-CLAUDIN-18 ANTIBODIES FOR TREATING CANCER | 2008 |
|
RU2571923C2 |
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| ANGIOGENESIS INHIBITION | 2008 |
|
RU2471498C2 |
| MACROPHAGE ACTIVATION MODULATION | 2012 |
|
RU2639553C2 |
| BTN2-SPECIFIC ANTIBODIES AND USE THEREOF | 2020 |
|
RU2821703C2 |
| APPLICATION OF HEPARIN-BINDING ANTAGONISTS IN INHIBITING BRADYKININ RELEASING | 2000 |
|
RU2251433C2 |
| MONOCLONAL ANTIBODIES AGAINST CLAUDIN-18 FOR TREATMENT OF CANCER | 2008 |
|
RU2682285C2 |
